Olfr417 inhibitors would be a specific category of chemical compounds designed to interact with and inhibit the olfactory receptor Olfr417. Olfactory receptors are a large family of G protein-coupled receptors (GPCRs) that are predominantly expressed in the sensory neurons of the olfactory epithelium and are responsible for the detection of odor molecules. Olfr417 is one such receptor that is involved in the complex molecular recognition and signal transduction processes that allow for the perception of specific odorants. Inhibitors of Olfr417 would be molecules that can bind to the receptor and prevent its activation by odorant molecules, effectively blocking the receptor's ability to initiate a cellular response to certain scents. Such inhibitors would require a high degree of specificity to ensure that they do not interfere with the multitude of other olfactory receptors with varying ligand specificities.
The development of Olfr417 inhibitors would necessitate a detailed understanding of the receptor's structure and the molecular dynamics of its interaction with odorants. Given the membrane-bound and highly dynamic nature of GPCRs, this is a challenging endeavor. The structural characterization of Olfr417 could involve techniques such as X-ray crystallography, cryo-electron microscopy, or nuclear magnetic resonance spectroscopy, which would provide insights into the three-dimensional arrangement of amino acids that form the binding pocket and the overall architecture of the receptor. With this structural information, the design of inhibitors would likely leverage computational approaches, including molecular docking and virtual screening, to predict and optimize the interaction of small molecules with the receptor's active or allosteric sites. These in silico methods would guide the synthesis of potential inhibitory compounds that are finely tuned to fit within the binding site of Olfr417 without activating the receptor.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and inhibits RNA polymerase, which prevents mRNA synthesis and could decrease the expression of genes such as olfactory receptors. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin can inhibit bacterial RNA polymerase, and at certain concentrations, it may affect eukaryotic cells by modulating gene expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits eukaryotic RNA polymerase II, which could lead to a reduction in mRNA synthesis for proteins, including olfactory receptors. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in translation, potentially reducing protein levels. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Puromycin causes premature chain termination during protein synthesis, which can decrease the overall levels of proteins including GPCRs. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can prevent peptide chain elongation, affecting the expression of proteins. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, leading to DNA damage and potentially affecting gene transcription. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA polymerase II transcription elongation, which could suppress the expression of specific genes. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases, which are important for cell cycle progression and gene transcription regulation. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic acid can modulate various signaling pathways and potentially influence gene expression indirectly. | ||||||